A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Recruiting now Phase 2 NCT06782490
Run by Celgene · for 18 to 70 · All sexes
What this study is about
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
Who can join (things the study team will check)
✅ You may be able to join if…
- Participants must have a multiple sclerosis (MS) diagnosis.
- Participants must have a history of spasticity due to MS for at least 6 months prior to Visit 1.
- Participants must have a Modified Ashworth Scale (mAS) score ≥2 in each of 2 muscle groups (at least one muscle group in the leg, excluding ankle plantar flexors) at Visit 1.
- Participants must have an Expanded Disability Status Scale (EDSS) score 3.0-6.5 at Visit 1.
🚫 You may not be able to join if…
- Participants must not have any concomitant disease or disorder that has symptoms of spasticity or that may influence the participant's level of spasticity.
- Participants must not have an acute MS exacerbation/relapse requiring treatment or alteration in disease modifying drug dose within 3 months of Visit 1 or Visit 2.
- Participants must not have a history of any substance abuse disorder as defined in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Diagnostic Criteria for Drug and Alcohol Abuse.
- Participants must not be currently taking a medication for spasticity that cannot be discontinued and washed out by Visit 2.
- Participants must not have used FAAH/MAGL inhibitor medication or any cannabinoid-related products (including cannabis, cannabidiol (CBD), or tetrahydrocannabinol (THC)) within 30 days prior to Visit 1.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Where this trial is running
- Alabama Neurology Associates, Birmingham, Alabama, United States
- Perseverance Research Center,LLC, Scottsdale, Arizona, United States
- Local Institution - 0017, Aurora, Colorado, United States
- Aqualane Clinical Research, Naples, Florida, United States
- USF Health, Tampa, Florida, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Neurology Center of New England, Foxborough, Massachusetts, United States
- Local Institution - 0071, Southfield, Michigan, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- University of Cincinnati Medical Center, Cincinnati, Ohio, United States
- Riverside Methodist Hospital, Columbus, Ohio, United States
- Local Institution - 0069, Columbus, Ohio, United States
+ 42 more sites.
Who to contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06782490.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.